Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis

Journal of the American Medical Association

Volumn 288, Issue 16, 2002, Pages 2015-2022

  Clarke, R ^a   Collins, R ^a   Lewington, S ^a   Donald, A ^a   Alfthan, G ^a   Tuomilehto, J ^a   Arnesen, E ^a   Bonaa, K ^a   Blacher, J ^a   Boers, G H J ^a   Bostom, A ^a   Bots, M L ^a   Grobbee, D E ^a   Brattstrom L ^a   Breteler, M M B ^a   Hofman, A ^a   Chambers, J C ^a   Kooner, J S ^a   Coull, B M ^a   Evans, R W ^a   Kuller, L H ^a   Evers, S ^a   Folsom, A R ^a   Freyburger, G ^a   Parrot, F ^a   Genest, J ^a   Dalery, K ^a   Graham, I M ^a   Daly, L ^a   Hoogeveen, E K ^a   Kostense, P J ^a   Stehouwer, C D A ^a   Hopkins, P N ^a   Jacques, P ^a   Selhub, J ^a   Luft, F C ^a   Jungers, P ^a   Lindgren, A ^a   Lolin, Y I ^a   Loehrer, F ^a   Fowler, B ^a   Mansoor, M A ^a   Malinow, M R ^a   Ducimetiere, P ^a   Nygard, O ^a   Refsum, H ^a   Vollset, S E ^a   Ueland, P M ^a   Omenn, G S ^a   Beresford, S A A ^a   Roseman, J M ^a   Parving, H H ^a   Gall, M A ^a   Perry, I J ^a   Ebrahim, S B ^a   Shaper, A G ^a   Robinson, K ^a   Jacobsen, D W ^a   Schwartz, S M ^a   Siscovick, D S ^a   Stampfer, M J ^a   Hennekens, C H ^a   Feskens, E J M ^a   Kromhout, D ^a   Ubbink, J ^a   Elwood, P ^a   Pickering, J ^a   Verhoef, P ^a   Von Eckardstein, A ^a   Schulte, H ^a   Assmann, G ^a   Wald, N ^a   Law, M R ^a   Whincup, P H ^a   Wilcken, D E L ^a   Sherliker, P ^a   Linksted, P ^a   Smith, G Davey ^a   more..

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; METHIONINE;

AMINO ACID BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; GENETIC VARIABILITY; HUMAN; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; LOADING TEST; LOGISTIC REGRESSION ANALYSIS; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE;

ADULT; AGED; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037164104     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.16.2015     Document Type: Review

References (73)

1. McCully KS. Vascular pathology of homocysteinemia. Am J Pathol. 1969;56:111-128.
2. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. J Clin Invest. 1976;57:1079-1082.
3. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia. N Engl J Med. 1991;324:1149-1155.
4. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995; 274:1049-1057.
5. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease. J Cardiovasc Risk. 1998;5: 229-232.
6. Clarke R, Lewington S, Donald A, et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk. 2001;8:363-369.
7. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150:341-353.
8. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992; 268:877-881.
9. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924-1930.
10. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
11. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995; 24:704-709.
12. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middleaged British men. Lancet. 1995;346:1395-1398.
13. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997;17:1947-1953.
14. Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WJ. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis. 1998; 140:349-356.
15. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: A 10-year follow-up. Arterioscler Thromb Vasc Biol 1998;18:1895-1901
16. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98:204-210.
17. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease. Arch Intern Med. 1998;158:862-867.
18. Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: The Rotterdam Study. Arch Intern Med. 1999;159:38-44.
19. Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: Prospective study in middle-aged men. Heart. 1999;82:448-454.
20. Genest JJ Jr, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
21. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994;59:940-948.
22. von Eckardstein A, Malinow MR, Upson B, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb. 1994; 14:460-464.
23. Hopkins PN, Wu LL, Wu J, et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1995; 15:1314-1320.
24. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26:795-800.
25. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction. Am J Epidemiol. 1996;143:845-859.
26. Malinow MR, Ducimetiere P, Luc G, et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction. Atherosclerosis. 1996;126:27-34
27. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA. 1997; 277:1775-1781
28. Silberberg J, Crooks R, Fryer J, et al. Gender differences and other determinants of the rise in plasma homocysteine after L-methionine loading. Atherosclerosis. 1997;133:105-110.
29. Verhoef P, Kok FJ, Kruyssen DA, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:989-995.
30. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 1997;96:412-417.
31. Joubran R, Asmi M, Busjahn A, Vergopoulos A, Luft FC, Jouma M. Homocysteine levels and coronary heart disease in Syria. J Cardiovasc Risk. 1998; 5:257-261.
32. Chambers JC, Obeid OA, Refsum H, et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian, Asian and European men. Lancet. 2000;355:523-527.
33. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P. Elevated plasma homocyst(e) ine concentration as a possible independent risk factor for stroke. Stroke 1990;21:572-576.
34. Dalery K, Lussier Cacan S, Selhub J, Davignon J, Latour Y, Genest J Jr. Homocysteine and coronary artery disease in French Canadian subjects. Am J Cardiol. 1995;75:1107-1111.
35. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Circulation. 1995;92:2825-2830.
36. Lolin YI, Sanderson JE, Cheng SK, et al. Hyperhomocysteinaemia and premature coronary artery disease in the Chinese. Heart. 1996;76:117-122.
37. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol. 1997;54:1276-1282.
38. Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia: A possible risk factor for arteriosclerotic cerebrovascular disease. Stroke. 1984;15:1012-1016.
39. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985; 313:709-715.
40. Dudman NP, Wilcken DE, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Arterioscler Thromb. 1993;13:1253-1260.
41. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988;71:227-233.
42. Andersson A, Isaksson A, Brattstrom L, Israelsson B, Hultberg B. Influence of hydrolysis on plasma homocysteine determination in healthy subjects and patients with myocardial infarction. Atherosclerosis. 1991;88:143-151.
43. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction. J Intern Med. 1995;237:381-388.
44. Mendis S, Athauda SB, Takashi K. Association between hyperhomocysteinemia and ischemic heart disease in Sri Lankans. Int J Cardiol. 1997;62:221-225.
45. Montalescot G, Ankri A, Chadefaux Vekemans B, et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol. 1997;60:295-300.
46. Chacko KA. Plasma homocysteine levels in patients with coronary heart disease. Indian Heart J. 1998; 50:295-299.
47. Dierkes J, Bisse E, Nauck M, et al. The diagnostic value of serum homocysteine concentration as a risk factor for coronary artery disease. Clin Chem Lab Med. 1998;36:453-457.
48. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and allcause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med. 1999; 159:1077-1080.
49. Blacher J, Montalescot G, Ankri A, et al. Hyperhomocysteinemia in coronary artery diseases. Arch Mal Coeur Vaiss. 1996;89:1241-1246.
50. Loehrer FM, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol. 1996;16:727-733.
51. Freyburger G, Labrouche S, Sassoust G, Rouanet F, Javorschi S, Parrot F. Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases. Thromb Haemost. 1997;77:466-471.
52. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-1124.
53. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138-141.
54. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230-236.
55. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study. Arterioscler Thromb Vasc Biol. 1998;18:133-138.
56. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int. 1999; 55:308-314.
57. Stampfer MA, Colditz G. Estrogen replacement therapy and coronary heart disease. Prev Med. 1991; 20:47-63.
58. Easton DF, Peto J, Babiker AG. Floating absolute risk: An alternative to relative risk in survival and casecontrol analysis avoiding an arbitrary reference group. Stat Med. 1991;10:1025-1035.
59. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements. BMJ. 1998;316:894-898.
60. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol. 2000;47:145-151.
61. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332:286-291.
62. Nygard O, Refsum H, Ueland PM, et al. Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr. 1997;65:136-143.
63. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
64. Kark JD, Selhub J, Adler B, et al. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med. 1999;131:321-330.
65. Voutilainen S, Lakka TA, Hamelahti P, Lehtimaki T, Poulsen HE, Salonen JT. Plasma total homocysteine concentration and the risk of acute coronary events: The Kuopio Ischaemic Heart Disease Risk Factor Study. J Intern Med. 2000;248:217-222.
66. Vollset SE, Refsum H, Tverdal A, etal. Plasma total homocysteine and cardiovascular disease and noncardiovascular mortality: The Hordaland Homocysteine Study. Am J Clin Nutr. 2001;74:130-136.
67. Knekt P, Reunanen A, Alfthan G, et al. Hyperhomocysteinemia: A risk factor or consequence of coro-nary heart disease? Arch Intern Med. 2001;161:1589-1594.
68. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281:1817-1821.
69. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet. 2001;358:1356-1360.
70. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease. Nat Genet. 1995; 10:111-113.
71. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr. 2000;72:315-323.
72. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, and the MTHFR Studies Collaboration. MTHFR C677C→T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA. 2002;288:2023-2031.
73. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? J Cardiovasc Risk. 1998;5:249-255.